Similar articles for PMID: 16334152

Year	Number of Results
1951	1
1970	1
1992	1
1993	2
1994	6
1995	1
1996	5
1997	3
1998	3
1999	8
2000	9
2001	9
2002	7
2003	20
2004	29
2005	28
2006	21
2007	16
2008	22
2009	18
2010	23
2011	25
2012	18
2013	9
2014	9
2015	5
2016	2
2017	3
2023	0

1

Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.

Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H. Prisack HB, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4615-21. Anticancer Res. 2005. PMID: 16334152 Free article.

2

Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.

Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S. Kariya S, et al. Radiat Med. 2005 May;23(3):189-94. Radiat Med. 2005. PMID: 15940066

3

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial.

4

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L. Bottini A, et al. Clin Cancer Res. 2000 Jul;6(7):2751-8. Clin Cancer Res. 2000. PMID: 10914720

5

Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.

Zhou B, Yang DQ, Xie F. Zhou B, et al. Chin Med J (Engl). 2008 Mar 5;121(5):387-91. Chin Med J (Engl). 2008. PMID: 18364105

6

Changes in tumour biological markers during primary systemic chemotherapy (PST).

Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, Fehm T. Neubauer H, et al. Anticancer Res. 2008 May-Jun;28(3B):1797-804. Anticancer Res. 2008. PMID: 18630463 Free article.

7

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.

Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T. Kröger N, et al. Clin Cancer Res. 2006 Jan 1;12(1):159-68. doi: 10.1158/1078-0432.CCR-05-1340. Clin Cancer Res. 2006. PMID: 16397038

8

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP. Petit T, et al. Breast Cancer Res Treat. 2010 Nov;124(2):387-91. doi: 10.1007/s10549-010-1142-2. Epub 2010 Sep 8. Breast Cancer Res Treat. 2010. PMID: 20824324

9

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Lee KH, et al. BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63. BMC Cancer. 2007. PMID: 17430582 Free PMC article.

10

Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed